A new takeover offer for U.S. biotech firm Baxalta would create one of the world's leading specialists in rare diseases.» Read More
Bayer CEO Werner Wenning signalled that the company is set to take a break from big acquisitions after a spate of deals that have catapulted it into leading positions in healthcare and crop science.
Rite Aid, the third-largest U.S. drugstore chain, posted a higher quarterly profit Thursday as an income tax benefit and a gain on asset sales offset acquisition costs.
The battle between two drug giants over the cervical cancer vaccine market is heating up. A study being published in the British medical journal, "The Lancet," says GlaxoSmithKline's shot called "Cervarix" may be different from Merck's Gardasil.
Shares of the wildly popular and volatile Dendreon were treading water on unremarkable, relatively low volume for most of the day today. Then, all of a sudden, around 2:30 there was a big spike in the stock and volume surged. With less than 15 minutes left until the closing bell more than 11 million shares have been traded. The daily average recently is nearly 24 million. The shares are up more than 10%. There's still a large, but smaller (month over month) short interest in the stock.
The huge auditorium at the McCormick Place Convention Center was packed to the rafters. It was standing room only in the 45-hundred seat theater, although the fire department wouldn't let people stand. The doctors, scientists, and educators at the American Diabetes Association's Annual Meeting came to see the rock stars of their world--Dr. Steven Nissen who wrote the controversial New England Journal of Medicine report questioning the safety of GlaxoSmithKline's Avandia and Dr. Phillip Home who wrote--also in NEJM--the subsequent interim analysis of a GSK-sponsored study that, so far, supports Avandia's safety.
Ventana told its shareholders Tuesday it recommends they "take no action at this time" in response to a $3 billion hostile takeover bid from Swiss drug maker Roche.
Shares of Ventana Medical Systems soared on Tuesday, on news that Roche Holding made a $3 billion tender offer for the company.
The new issue market is on track for its best year since 2000.
So, I'm back at the McCormick Convention Center in Chicago for the second time this month. We were here for ASCO--the cancer conference--at the beginning of June. But this trip is much different. Unlike ASCO, the American Diabetes Association which is holding its annual meeting here is letting us broadcast from inside the building! ASCO would not, has not and seems like never will let us work within the huge halls. A spokesman claims we'd cause a "media circus" and that the financial media threaten to compromise the "scientific integrity" of ASCO.
Did the Bear Stearns hedge-fund blowup scare you out of the market? Here are some picks to get you back in.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Drug maker Schering-Plough said Monday it received expanded European approval for a combination therapy of Pegintron and Rebetol to treat hepatitis C patients who are also infected with HIV.
With the pipeline this company has, Cramer thinks this $14 stock could hit $20 by this time next year.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
The tables have turned. Over the past couple of years I've been to a number of pharmaceutical industry related and drug company events--where the security and paranoia have been noticeably increased over what I referred to as "The Michael Moore Effect". Ever since it became known that the documentary filmmaker was setting his sites on healthcare the companies I cover have been on heightened alert. But, at least for now, I think they can let their guard down.
Pfizer said after markets closed Wednesday that U.S. health regulators will approve its novel AIDS drug called maraviroc once certain conditions have been met, although the world's biggest drugmaker did not elaborate on what was necessary to obtain an outright approval.
We can’t all be experts at everything, which is why we have people who are experts at something. Having said that, I’ll let you in on one of my little secrets -- how to tell when a pharmaceutical story has significance. ... Also: a seemingly innocuous headline -- about Expedia -- has plenty of hidden meaning.
Bristol-Myers Squibb's future looks a lot clearer. A federal judge this morning ruled the patent on the bloodthinner Plavix which Bristol shares with Sanofi-Aventis is valid. And Judge Sidney Stein added the companies are entitled to injunctive relief and damages. Money. It'll come from the scrappy, pesky, Canadian, privately-held generic drug company "Apotex". Last summer Apotex took advantage of a legal loophole in a sweet side deal it negotiated with Bristol and launched generic Plavix.
A U.S. judge on Tuesday ruled that the patent on the multibillion-dollar blood clot-preventing drug Plavix is valid, handing a major victory to Bristol-Myers Squibb and Sanofi-Aventis.
A U.S. judge Tuesday ruled that the patent on the multibillion-dollar blood clot preventer Plavix is valid, handing a major victory to Bristol-Myers Squibb and Sanofi-Aventis. Shares of both companies rose on the news.
U.S. health regulators have granted priority review for Bristol-Myers Squibb experimental breast cancer drug ixabepilone, and an approval decision on the medicine could come by late October, the company said on Tuesday.
Earnings news and clinical trial data were some of the catalysts behind the most actively traded stocks on Monday.